Background: Lymphangioleiomyomatosis (LAM) is a progressive lungs disease that affects women at reproductive years. Sirolimus inhibits mammalian target of rapamycin (mTOR) and its administration in past studies was hopeful in treatment of patients with LAM. The aim of this study was to evaluate sirolimus therapy on lung function in LAM patients. Methods: We conducted a trial to evaluate the ef...

Sirolimus is a potent immunosuppressive agent administered as prophylactic agent to prevent rejection after organ transplantation. Sirolimus must be used within a narrow therapeutic window. Due to inter- and intra-variability, sirolimus blood concentrations may be affected, therefore, there is no possibility of predicting the sirolimus blood concentrations based on the dose patients received. T...

sirolimus is a potent immunosuppressive agent administered as prophylactic agent to prevent rejection after organ transplantation. sirolimus must be used within a narrow therapeutic window. due to inter- and intra-variability, sirolimus blood concentrations may be affected, therefore, there is no possibility of predicting the sirolimus blood concentrations based on the dose patients received. t...

Rapamycin, also known as sirolimus, inhibits the mTOR pathway in complex diseases such cancer, and its downstream targets are ribosomal S6 kinases (RPS6K). Sirolimus is involved regulating cell growth survival through roles mediation of epidermal factor signaling. However, systemic efficacy sirolimus regulation unclear. The purpose this study to determine drug using computational methods drug-i...

Background Pediatric vascular anomalies comprise a heterogeneous group of clinical disorders of varying severity. These anomalies are divided into vascular tumors or vascular malformations. Different therapeutic strategies have been used depending on the pathology in question. In recent years, mammalian target of rapamycin (mTOR) inhibitors have been explored as a therapeutic option in patients...

immunosuppressants require therapeutic drug monitoring because of their narrow therapeutic index and significant inter-individual variability in blood concentrations. this variability can be because of factors like drug-nutrient interactions, drug-disease interactions, renal-insufficiency, inflammation and infection, gender, age, polymorphism and liver mass. drug monitoring is widely practiced ...

STUDY OBJECTIVE To determine an appropriate empiric oral sirolimus dose adjustment when given concurrently with posaconazole oral suspension in patients who undergo hematopoietic stem cell transplant (HSCT). DESIGN Retrospective cohort study. SETTING Comprehensive cancer center in the United States. SUBJECTS Seventy five allogeneic HSCT patients who received posaconazole oral suspension a...

Nanoparticles are useful delivery vehicles for promising drug candidates that face obstacles for clinical applicability. Sirolimus, an inhibitor of mammalian target of rapamycin has gained attention for targeted anticancer therapy, but its clinical application has been limited by its poor solubility. This study was designed to enhance the feasibility of sirolimus for human cancer treatment. Pol...

STUDY OBJECTIVES To assess the use and safety of concurrent administration of voriconazole and sirolimus-which is contraindicated-and to determine approaches for appropriately managing patients who receive both drugs. DESIGN Retrospective medical record review. SETTING University-affiliated medical center. PATIENTS Thirty-one cases in 23 inpatients who received at least one dose of vorico...

BACKGROUND Sirolimus-eluting stents may have clinical advantages over bare-metal stents in the extremely proliferative environment of the neonatal arterial duct. However, sirolimus has immunosuppressive actions and little is known regarding sirolimus pharmacokinetics in the newborn. METHODS AND RESULTS This is a retrospective review of sirolimus pharmacokinetics in neonates who underwent siro...